Curated News
By: NewsRamp Editorial Staff
June 24, 2026

Pharmaceutical Omega-3 API Market to Hit $2.3B by 2036

Discuss on Substack View History of this news story on GitHub
Original Source

TLDR

  • API suppliers with strong purification and regulatory depth will capture market leadership as demand for pharmaceutical omega-3 APIs doubles by 2036.
  • The market uses advanced purification and regulatory documentation like DMF and CEP to produce high-purity omega-3 APIs for prescription therapies.
  • Pharmaceutical omega-3 APIs help reduce cardiovascular risk and manage severe hypertriglyceridemia, improving patient outcomes and quality of life.
  • Icosapent ethyl leads the API landscape with 41.6% market share, driving growth in prescription EPA therapies for heart health.

Impact - Why it Matters

This news matters because it highlights a shift from over-the-counter omega-3 supplements to prescription-grade therapies that clinically reduce cardiovascular risk. For patients, this means more effective treatments for high triglycerides and heart disease. For healthcare systems, growing reliance on purified APIs ensures consistent drug quality and regulatory compliance. Investors and pharmaceutical companies gain insights into a specialized market driven by EPA therapies and regulatory rigor, which will shape future supply chain strategies and therapeutic innovations.

Summary

The global Pharmaceutical Omega-3 API Market is poised for significant growth, driven by rising prescription demand for cardiovascular-risk reduction therapies. According to a report by Future Market Insights, the market is projected to grow from USD 1.1 billion in 2026 to USD 2.3 billion by 2036, at a CAGR of 7.7%. Unlike consumer supplements, pharmaceutical-grade omega-3 active pharmaceutical ingredients (APIs) are increasingly valued for clinical efficacy in managing severe hypertriglyceridemia and residual cardiovascular risk. Key players include KD Pharma, BASF Pharma Solutions, Croda International, and Amarin Corporation, with icosapent ethyl leading the API landscape. The shift from commodity marine oils to highly purified, dossier-backed APIs supported by Drug Master Files (DMF) and Certificates of Suitability (CEP) reflects growing buyer preference for regulatory compliance and batch consistency.

Marine fish oil remains the dominant feedstock, while ethyl ester concentrates lead product form demand, accounting for 64.2% of market share in 2026. The United States is the largest market, projected to reach USD 726.4 million by 2036, while Saudi Arabia is the fastest-growing country at 9.2% CAGR. Innovation focuses on high-purity molecular separation technologies and supply chain traceability. Challenges include high purification costs, supplier switching difficulties, and pricing pressure from payers. The market is segmented by API type, product form, regulatory filing, source material, end-use application, and supply model, with contract supply to finished-dose manufacturers leading at 55.8% share.

Investment is shifting toward vertically integrated suppliers with advanced purification assets. Strategic partnerships and long-term supply agreements are becoming crucial. The future outlook emphasizes expansion of prescription EPA therapies, stronger cardiovascular prevention strategies, and improved purification technologies. Companies combining marine sourcing security with high-quality API production and regulatory expertise will lead market growth. For more details, access the complete report in PDF format here.

Source Statement

This curated news summary relied on content disributed by 24-7 Press Release. Read the original source here, Pharmaceutical Omega-3 API Market to Hit $2.3B by 2036

blockchain registration record for this content.